Thrivent Financial for Lutherans Acquires 684,802 Shares of Illumina, Inc. $ILMN

Thrivent Financial for Lutherans grew its stake in Illumina, Inc. (NASDAQ:ILMN) by 1,558.0% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 728,755 shares of the life sciences company’s stock after acquiring an additional 684,802 shares during the period. Thrivent Financial for Lutherans’ holdings in Illumina were worth $69,528,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of ILMN. Envestnet Portfolio Solutions Inc. grew its stake in Illumina by 0.8% in the second quarter. Envestnet Portfolio Solutions Inc. now owns 12,074 shares of the life sciences company’s stock valued at $1,152,000 after purchasing an additional 99 shares in the last quarter. Parkside Financial Bank & Trust grew its stake in shares of Illumina by 65.7% in the second quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company’s stock valued at $28,000 after buying an additional 115 shares in the last quarter. Arkadios Wealth Advisors increased its holdings in Illumina by 1.7% during the second quarter. Arkadios Wealth Advisors now owns 9,130 shares of the life sciences company’s stock worth $871,000 after buying an additional 157 shares during the last quarter. IMA Advisory Services Inc. raised its position in Illumina by 6.2% during the second quarter. IMA Advisory Services Inc. now owns 2,853 shares of the life sciences company’s stock worth $272,000 after acquiring an additional 167 shares in the last quarter. Finally, Whipplewood Advisors LLC lifted its stake in Illumina by 22.2% in the second quarter. Whipplewood Advisors LLC now owns 929 shares of the life sciences company’s stock valued at $89,000 after acquiring an additional 169 shares during the last quarter. Institutional investors own 89.42% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on ILMN. Barclays restated an “underweight” rating on shares of Illumina in a research note on Monday. Canaccord Genuity Group lifted their price target on Illumina from $105.00 to $112.00 and gave the stock a “hold” rating in a report on Friday, October 31st. Cowen reissued a “hold” rating on shares of Illumina in a research report on Friday, October 31st. Wall Street Zen upgraded Illumina from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Finally, UBS Group lifted their target price on Illumina from $110.00 to $120.00 and gave the stock a “neutral” rating in a research note on Friday, October 31st. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, thirteen have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Illumina presently has a consensus rating of “Hold” and an average price target of $115.00.

Insider Buying and Selling

In other news, Director Scott Gottlieb acquired 500 shares of the stock in a transaction on Monday, November 3rd. The shares were purchased at an average price of $122.13 per share, for a total transaction of $61,065.00. Following the transaction, the director directly owned 12,523 shares of the company’s stock, valued at approximately $1,529,433.99. This represents a 4.16% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.17% of the stock is currently owned by corporate insiders.

Illumina Stock Down 1.2%

Illumina stock opened at $134.87 on Monday. The company’s 50-day moving average price is $114.71 and its two-hundred day moving average price is $102.88. The company has a quick ratio of 1.12, a current ratio of 1.43 and a debt-to-equity ratio of 0.42. The stock has a market cap of $20.61 billion, a P/E ratio of 30.24, a P/E/G ratio of 2.41 and a beta of 1.44. Illumina, Inc. has a twelve month low of $68.70 and a twelve month high of $153.06.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, October 30th. The life sciences company reported $1.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.16 by $0.18. Illumina had a return on equity of 29.21% and a net margin of 16.40%.The company had revenue of $1.08 billion during the quarter, compared to analysts’ expectations of $1.07 billion. During the same quarter in the previous year, the company posted $1.14 earnings per share. The business’s revenue was up .4% on a year-over-year basis. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. As a group, analysts expect that Illumina, Inc. will post 4.51 EPS for the current year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.